文献速递肝病消化道肿瘤与早癌

肝硬化患者监测期间检出的非肝细胞癌局灶性病变的临床与财务负担

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis.
PubMed 文献 · Hepatology · 2023-09-29

该研究回顾性分析了法国57个三级中心纳入肝癌监测项目的3295例肝硬化患者,随访59.8个月,非肝细胞癌肝脏局灶性病变5年累积发生率为21.8%,其诊断检查平均费用为1087欧元,虽不影响预后但带来显著经济负担。

要点

  • 肝硬化患者监测中非肝细胞癌局灶性病变常见,5年累积发生率为21.8%。
  • 非肝细胞癌局灶性病变诊断检查平均费用为1087欧元,肝细胞癌为1572欧元。
  • 良性或未明确性质的非肝细胞癌局灶性病变患者5年生存率与无局灶性病变者相似(92% vs. 88%,p=0.07)。

核心结论

  • 非肝细胞癌局灶性病变在肝硬化患者中频繁检出,不影响预后,但引发大量费用。
  • 在未来的个性化监测策略的成本效益分析中必须考虑这一负担。

研究设计与样本

  • 回顾性分析法国57个三级中心纳入肝癌监测项目的患者(ANRS CirVir和CIRRAL队列、HCC 2000试验),共3295例,随访59.8个月。
  • 评估非标准化检查流程的总费用,并估算全人群及每检出病变的平均费用。

主要发现

  • 391例(11.9%)发生肝细胞癌,5年发生率为12.1%。
  • 633例(19.2%)发生非肝细胞癌局灶性病变,5年发生率为21.8%。
  • 非肝细胞癌局灶性病变特征描述每年需中位额外0.7次检查。
  • 11.8%的非肝细胞癌局灶性病变在召回程序后未获确认,19.6%性质未确定。
  • 65.1%确诊为良性肝脏病变,3.5%诊断为恶性肿瘤。

关键数值与推荐

  • 良性或未明确性质的非肝细胞癌局灶性病变患者5年生存率为92%,无任何局灶性病变患者为88%,p=0.07。
  • 非肝细胞癌局灶性病变平均诊断检查费用为1087欧元,肝细胞癌为1572欧元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HCC surveillance is challenged by the detection of hepatic focal lesions (HFLs) of other types. This study aimed to describe the incidence, characteristics, outcomes, and costs of non-HCC HFL detected during surveillance. APPROACH AND RESULTS: We retrospectively analyzed nonstandardized workup performed in French patients included in HCC surveillance programs recruited in 57 French tertiary centers (ANRS CirVir and CIRRAL cohorts, HCC 2000 trial). The overall cost of workup was evaluated, with an estimation of an average cost per patient for the entire population and per lesion detected. A total of 3295 patients were followed up for 59.8 months, 391 (11.9%) patients developed HCCs (5-year incidence: 12.1%), and 633 (19.2%) developed non-HCC HFLs (5-year incidence: 21.8%). Characterization of non-HCC HFL required a median additional of 0.7 exams per year. A total of 11.8% of non-HCC HFLs were not confirmed on recall procedures, and 19.6% of non-HCC HFLs remained undetermined. A definite diagnosis of benign liver lesions was made in 65.1%, and malignant tumors were diagnosed in 3.5%. The survival of patients with benign or undetermined non-HCC HFL was similar to that of patients who never developed any HFL (5-year survival 92% vs. 88%, p = 0.07). The average cost of the diagnostic workup was 1087€ for non-HCC HFL and €1572 for HCC. CONCLUSIONS: Non-HCC HFLs are frequently detected in patients with cirrhosis, and do not impact prognosis, but trigger substantial costs. This burden must be considered in cost-effectiveness analyses of future personalized surveillance strategies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Nahon P, Layese R, Ganne-Carrié N, et al. The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis. Hepatology. 2023. PMID: 37774387. doi:10.1097/HEP.0000000000000615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。